Clinical Trial Update: The Anifrolumab PRIM Program

View source ↗

Summary

The document indicates that AstraZeneca's Anifrolumab PRIM Program for systemic lupus erythematosus is currently recruiting participants.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Anifrolumab (anifrolumab)

Snippet

Sponsor: AstraZeneca | Conditions: Systemic Lupus Erythematosus | Status: RECRUITING